Being classified as a CYP2D6 intermediate metabolizer means your body breaks down certain medications more slowly than most people, but not as slowly as someone classified as a poor metabolizer. CYP2D6 is a liver enzyme responsible for processing roughly 20 to 25 percent of commonly prescribed drugs, and your genetic version of it works at reduced capacity.1PubMed Central. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine In practice, that can mean higher-than-expected drug levels for some medications, lower-than-expected activation for others, and a need for dose adjustments that your prescriber may or may not know about yet.
How You End Up as an Intermediate Metabolizer
You inherit two copies of the CYP2D6 gene, one from each parent. Each copy is assigned a label, called a star allele, that reflects how well it works. Some alleles produce a fully functional enzyme, some produce a version with reduced activity, and some produce nothing at all. The CYP2D6 gene is one of the most variable genes in the human genome, with single-letter changes, insertions, deletions, and even whole-gene duplications or deletions all documented.2PubMed Central. A Review of the Important Role of CYP2D6 in Pharmacogenomics To make sense of this complexity, labs use an activity score system: each allele gets a numerical value (typically 0, 0.25, 0.5, or 1), and the two scores are added together.3PubMed. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype
A total activity score of roughly 1 to 1.5 places you in the intermediate metabolizer category. You might carry one normal-function allele (value of 1) paired with a non-functional one (value of 0), giving you a score of 1. Or you might carry one normal allele paired with a decreased-function allele like *41 or *10 (value of 0.5), landing at 1.5. There are several common decreased-function alleles: *10 and *41 appear frequently in East Asian and South Asian populations respectively, while *17, first identified in individuals of African descent, carries mutations that reduce the enzyme’s activity.4Molecular Pharmacology. A Combination of Mutations in the CYP2D6*17 (CYP2D6Z) Allele Causes Alterations in Enzyme Function The non-functional *4 allele is the most common cause of zero activity in people of European ancestry, while *5 represents a whole-gene deletion.5medRxiv. Genetic ancestral patterns in CYP2D6 alleles: structural variants, rare variants, and clinical associations in 479,144 UK Biobank genomes
The upshot is that intermediate metabolizers are a genetically diverse group. Two people sharing the same “intermediate metabolizer” label can have meaningfully different enzyme output depending on which specific alleles they carry. Someone with an activity score of 1.0 has less enzyme function than someone at 1.5, and the drug classes affected can differ depending on the underlying mutations. This is one reason why the intermediate metabolizer category sometimes feels imprecise compared with the cleaner definitions of poor or normal metabolizers.
Why Ancestry Matters for Your Alleles
The mix of CYP2D6 alleles circulating in a population varies dramatically by geographic ancestry. In European populations, the most common alleles are *2 (normal function) and *4 (non-functional). South Asian populations carry high frequencies of *2 and *41 (decreased function). African populations show a distinct profile dominated by *1, *29, and *17.6PubMed Central. Relevance of CYP2D6 Gene Variants in Population Genetic Differentiation East Asian populations carry high rates of the decreased-function *10 allele, which means a larger share of people in these groups fall into the intermediate metabolizer range.
An important nuance here is that even among people who share the same intermediate metabolizer classification, the actual enzyme activity can differ across ethnic groups. A study examining this found that Asian carriers of decreased-function alleles tended to show somewhat higher CYP2D6 activity than White or African American carriers with the same classification, at least for certain test drugs. The researchers concluded this was driven by differences in which specific alleles are common in each group rather than by inherent differences in how identical alleles perform.7PubMed Central. Does ethnicity impact CYP2D6 genotype-phenotype relationships? The takeaway is that an intermediate metabolizer label does not mean the exact same thing for every person, and ancestral background adds a layer of variability that clinicians are only beginning to account for.
Drugs That Are Most Affected
CYP2D6 handles about a quarter of all commonly prescribed medications, but its impact is not equal across all of them. Some drugs rely on CYP2D6 as their primary route of breakdown. For others, CYP2D6 is one of several enzymes involved, and alternative pathways can compensate when CYP2D6 is sluggish. The drugs where intermediate metabolizer status matters most tend to fall into a few key categories.
Opioid Pain Medications
Codeine, tramadol, and hydrocodone are prodrugs, meaning they need CYP2D6 to convert them into their active, pain-relieving forms. Codeine, for instance, must be converted to morphine. If your CYP2D6 enzyme is running at reduced speed, you produce less of the active compound. The clinical consequence is real: intermediate and poor metabolizers face an increased risk of getting inadequate pain relief from these medications.8PubMed Central. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients If you have ever taken codeine and felt like it did nothing, your CYP2D6 status could be why. Most clinical guidelines now recommend that poor metabolizers avoid these drugs altogether; the advice for intermediate metabolizers is more cautious, often suggesting an alternative opioid that does not depend on CYP2D6 activation, or closer monitoring.
Antidepressants
Many widely prescribed antidepressants are metabolized by CYP2D6, including several SSRIs like fluoxetine and paroxetine, and SNRIs like venlafaxine. The effect here is the opposite of what happens with codeine: instead of producing too little active drug, you clear the drug more slowly, so it builds up. For venlafaxine specifically, intermediate metabolizers show lower clearance of the parent drug compared to normal metabolizers, leading to higher circulating levels.9PubMed. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression A meta-analysis confirmed that the relationship between CYP2D6 status and venlafaxine drug levels is consistent and clinically meaningful across multiple studies.10PubMed. The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis
For tricyclic antidepressants like nortriptyline and amitriptyline, the Clinical Pharmacogenetics Implementation Consortium (CPIC) has published specific dose guidance: intermediate metabolizers may benefit from a 25 percent reduction of the standard recommended dose.11PubMed Central. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update This is one of the more concrete guideline recommendations available for intermediate metabolizers, since many other drug classes still lack formal dosing adjustments for this group.
Tamoxifen for Breast Cancer
Tamoxifen is another prodrug that depends on CYP2D6 for activation, specifically conversion into its most potent form, endoxifen. In a large clinical trial, intermediate metabolizers on tamoxifen had endoxifen levels about 32 percent lower than normal metabolizers (0.38 versus 0.56 ng/mL per mg of tamoxifen).12Annals of Oncology. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial The question of whether those lower endoxifen levels actually translate into worse cancer outcomes has been debated for years. The evidence is not as clean as researchers once hoped; some large studies find reduced benefit, while others find the effect is smaller than expected.
One practical response has been to try increasing the tamoxifen dose for intermediate and poor metabolizers. A dose-escalation study found that when guided by CYP2D6 genotype, intermediate metabolizers’ endoxifen levels could be raised from about 17.8 nM to 30.3 nM, roughly into the normal range, without a meaningful increase in side effects.13PubMed Central. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects This approach is being explored but is not yet standard practice everywhere.
ADHD Medications and Antipsychotics
Atomoxetine, a non-stimulant ADHD medication, is almost entirely dependent on CYP2D6 for its metabolism. The impact of being an intermediate metabolizer is substantial: drug exposure in intermediate metabolizers is roughly double that of normal metabolizers.14PubMed. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data Poor metabolizers had nearly tenfold higher exposure, which highlights how the intermediate category sits on a continuum rather than forming a sharp boundary. For atomoxetine, intermediate metabolizers often tolerate standard starting doses but may need slower uptitration and may reach therapeutic levels at lower final doses than normal metabolizers.
Several antipsychotic medications, including risperidone and aripiprazole, are also processed by CYP2D6. The FDA label for aripiprazole already includes guidance for poor metabolizers, and intermediate metabolizers can experience higher plasma drug levels that sometimes manifest as more pronounced sedation or other side effects.
Heart Medications
Metoprolol, a widely used beta-blocker for high blood pressure and heart failure, is metabolized primarily by CYP2D6. A clinical study found that poor and intermediate metabolizers showed a significantly greater reduction in heart rate compared with normal metabolizers, as expected from higher drug levels. Interestingly, blood pressure response and rates of adverse effects were not significantly different across groups.15PubMed Central. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate The practical implication is that if you are an intermediate metabolizer on metoprolol and your heart rate drops lower than your prescriber expects, your CYP2D6 status could explain why, even if your blood pressure response seems normal.
Phenoconversion and Temporary Status Changes
Your genetic CYP2D6 status is fixed for life, but your functional status can change temporarily. This happens through a phenomenon called phenoconversion, where a drug you are taking inhibits the CYP2D6 enzyme and effectively pushes your metabolism into a lower category. Fluoxetine and paroxetine are potent CYP2D6 inhibitors. If you are a genotypic intermediate metabolizer and start taking fluoxetine for depression, your effective CYP2D6 activity may drop to poor metabolizer levels. Any other CYP2D6-dependent drug you take alongside it will behave as though you have almost no enzyme activity. Bupropion, quinidine, and certain antihistamines like diphenhydramine also inhibit CYP2D6 to varying degrees.
Phenoconversion is one of the most clinically underappreciated aspects of CYP2D6 pharmacogenetics. A genetic test gives you your baseline, but it cannot account for what other medications are doing to your enzyme function in real time. This is why a medication review, not just a genetic result, is necessary to predict how you will actually handle a CYP2D6-dependent drug.
Getting Tested and Understanding Your Results
CYP2D6 testing is typically ordered by a physician or pharmacist, though direct-to-consumer testing companies also offer it. The test is usually done with a cheek swab or blood draw. Results come back as a genotype (which specific alleles you carry) and a predicted phenotype (your metabolizer category). Testing turnaround varies widely: a study across eight major medical institutions found a median time to results of 10 days, with a range stretching from 3 to 37 days.16PubMed Central. CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial
One challenge with CYP2D6 testing is the gene’s structural complexity. The gene sits in a region of the genome that is unusually difficult to read accurately. Copy number variations, hybrid genes formed by recombination with the neighboring CYP2D7 pseudogene, and certain sequence variants within probe-binding regions can all produce misleading results. A study investigating this problem found that certain CYP2D6 arrangements generate false-positive signals for gene deletions or confusing discordant calls that require careful interpretation.17PubMed Central. Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization Not all testing platforms detect the same set of variants, so the comprehensiveness of your result depends on which lab and technology your provider uses. If your result seems inconsistent with your drug responses, a more comprehensive test may be worthwhile.
How Hospitals Actually Use Your Results
Even when a CYP2D6 test is ordered and results are available, using those results to change prescribing is not automatic. A multi-site investigation of hospitals implementing CYP2D6 testing found that while all institutions put the results into the electronic health record, the way they acted on them varied. Some hospitals provided genotype-specific drug recommendations alongside the lab result. Most had a pharmacist available to help interpret findings. About five of the eight sites studied had built electronic alerts that would trigger when a CYP2D6-sensitive drug was prescribed to someone with a known genotype.18Genetics in Medicine. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing The most common triggers were codeine, tramadol, and antidepressants.
The gap between having results and acting on them remains real. In one trial of CYP2D6-guided opioid therapy in cancer patients, only about a quarter of physicians acknowledged the genotype results in their clinic notes, and among patients who received a specific recommendation to change therapy, fewer than one in five actually had their medication changed accordingly.16PubMed Central. CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial This is a sobering finding for anyone expecting that getting tested will automatically translate into personalized prescribing. If you have results, you may need to be your own advocate: bring a printed copy to every new prescriber, ask your pharmacist to flag it, and ask specifically whether any new prescription is CYP2D6-dependent.
Does Your Metabolizer Status Change with Age?
A question that comes up for parents of children who have been tested is whether the result will still be accurate as the child grows. A longitudinal study tracking CYP2D6 activity during adolescence found reassuring news: genetic variation in CYP2D6 had by far the largest influence on enzyme activity, while age, weight, height, and pubertal maturation had only small effects.19PubMed Central. A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence In other words, a child genotyped as an intermediate metabolizer at age 10 will almost certainly still be an intermediate metabolizer at age 25. The enzyme does mature during early life, with newborns having lower CYP2D6 activity overall, but the relative ranking among metabolizer groups stays consistent once the enzyme has reached adult levels.
Knowing Your Status Can Change How You Feel About Treatment
There is an underappreciated psychological dimension to pharmacogenomic testing. Research into patient perceptions has found that people who learn their CYP2D6 status want to understand the treatment options available and the reasoning behind a genotype-guided drug choice. Perhaps more interesting, patients reported being more willing to tolerate a medication’s side effects if they knew, based on their genetic results, that the drug was more likely to work for them. A separate study found that patients who were informed of their pharmacogenomic results showed higher medication adherence compared with controls who were not told.20PubMed Central. Assessment of Patient Perceptions of Genomic Testing to Inform Pharmacogenomic Implementation For intermediate metabolizers in particular, who sit in a gray zone where dose adjustments are sometimes subtle, understanding the rationale behind a smaller starting dose or a switch to an alternative drug can make the difference between sticking with a treatment plan and abandoning it.
Why CYP2D6 Is So Variable in the First Place
It is worth stepping back and asking why this enzyme is so genetically diverse across the human population. The answer appears to be dietary history. CYP2D6 is part of a large family of detoxification enzymes that evolved to neutralize plant-derived toxins, particularly alkaloids found in foods and medicinal plants. Gene duplications in the CYP2D6 region reflect ancient dietary pressures, where populations exposed to higher levels of plant alkaloids developed extra copies of the gene to metabolize them more efficiently.21PubMed Central. Dietary-Driven Gene Expansion Evidence of both stabilizing selection and population-specific selection on CYP genes suggests that different human groups were exposed to different suites of plant toxins, driving different genetic outcomes.22PubMed Central. Revealing the paradox of drug reward in human evolution
The irony is that the same genetic diversity that helped human populations survive varied diets now creates a headache for modern pharmacology. The drugs CYP2D6 metabolizes were designed for a “typical” enzyme activity level, but there is no single typical: the population contains a wide spectrum of CYP2D6 function, and intermediate metabolizers represent one large slice of that spectrum. In some populations, particularly those of East Asian ancestry where decreased-function alleles are common, intermediate metabolizers may actually be the most frequent phenotype group, making the “normal metabolizer” label something of a misnomer as a baseline assumption.